https://www.selleckchem.com/pr....oducts/talabostat.ht
A strong consistency between immunohistochemistry-digital image analysis and real-time quantitative reverse transcription polymerase chain reaction results was evident. Alterations in the mRNA levels and endometrial morphology returned to a pretreatment phenotype after the cessation of PRM exposure. The endometrial impact of the modulation of progesterone receptor pathways with PRM (UPA) treatment is reversible. Ulipristal acetate versus conventional management of heavy menstrual bleeding (UCON) trial (EudraCT 2014-003408-65; REC14/L
Like
Comment
Share
